Literature DB >> 10516002

A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.

A Trkola1, J Matthews, C Gordon, T Ketas, J P Moore.   

Abstract

We describe here a cell line-based assay for the evaluation of human immunodeficiency virus type 1 (HIV-1) neutralization. The assay is based on CEM.NKR cells, transfected to express the HIV-1 coreceptor CCR5 to supplement the endogenous expression of CD4 and the CXCR4 coreceptor. The resulting CEM.NKR-CCR5 cells efficiently replicate primary HIV-1 isolates of both R5 and X4 phenotypes. A comparison of the CEM.NKR-CCR5 cells with mitogen-activated peripheral blood mononuclear cells (PBMC) in neutralization assays with sera from HIV-1-infected individuals or specific anti-HIV-1 monoclonal antibodies shows that the sensitivity of HIV-1 neutralization is similar in the two cell types. The CEM.NKR-CCR5 cell assay, however, is more convenient to perform and eliminates the donor-to-donor variation in HIV-1 replication efficiency, which is one of the principal drawbacks of the PBMC-based neutralization assay. We suggest that this new assay is suitable for the general measurement of HIV-1 neutralization by antibodies.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10516002      PMCID： PMC112928     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  77 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

Review 2.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

3.  Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.

Authors:  D C Montefiori; T G Evans
Journal:  AIDS Res Hum Retroviruses       Date:  1999-05-20       Impact factor: 2.205

4.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages.

Authors:  B Lee; M Sharron; L J Montaner; D Weissman; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Authors:  G A Donzella; D Schols; S W Lin; J A Esté; K A Nagashima; P J Maddon; G P Allaway; T P Sakmar; G Henson; E De Clercq; J P Moore
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

6.  Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions.

Authors:  K Toyoshima; P K Vogt
Journal:  Virology       Date:  1969-07       Impact factor: 3.616

7.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Authors:  M C Gauduin; P W Parren; R Weir; C F Barbas; D R Burton; R A Koup
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

9.  Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

Authors:  A Trkola; W A Paxton; S P Monard; J A Hoxie; M A Siani; D A Thompson; L Wu; C R Mackay; R Horuk; J P Moore
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.

Authors:  B J Doranz; K Grovit-Ferbas; M P Sharron; S H Mao; M B Goetz; E S Daar; R W Doms; W A O'Brien
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307
View more
  117 in total

1.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

3.  Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.

Authors:  Dong Sung An; F Xiao-Feng Qin; Vincent C Auyeung; Si Hua Mao; Sam K P Kung; David Baltimore; Irvin S Y Chen
Journal:  Mol Ther       Date:  2006-07-17       Impact factor: 11.454

4.  Rev-dependent indicator T cell line.

Authors:  Yuntao Wu; Margaret H Beddall; Jon W Marsh
Journal:  Curr HIV Res       Date:  2007-07       Impact factor: 1.581

5.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

6.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

7.  Direct observation of chemokine receptors 5 on T-lymphocyte cell surfaces using fluorescent metal nanoprobes 2: Approximation of CCR5 populations.

Authors:  Jian Zhang; Yi Fu; Ge Li; Richard Y Zhao; Joseph R Lakowicz
Journal:  Biochem Biophys Res Commun       Date:  2011-02-26       Impact factor: 3.575

8.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.

Authors:  Lesley A Bergmeier; Kaboutar Babaahmady; Jeffrey Pido-Lopez; Kate J Heesom; Charles G Kelly; Thomas Lehner
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.